FDA Brief

Warning letters Drugs

FDA warning letter to

American Cleaning Solutions

High riskIssued Sep 6, 2022Posted Oct 18, 2022Division of Pharmaceutical Quality Operations I

FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.

What happened

FDA inspected the Long Island City, NY drug manufacturing facility from March 7 to March 28, 2022. Investigators found inadequate cleaning and maintenance of equipment also used for pesticides and industrial cleaners, no process validation or equipment qualification, missing incoming component testing, and weak quality-control oversight. FDA also found Secure Hand Sanitizer labeled as 70% isopropyl alcohol had been made with ethanol, and cited repeat observations from a 2016 inspection.

What FDA found

  1. The company lacked adequate written cleaning and maintenance procedures and had rust, dirt, debris, and grease on drug manufacturing equipment.

    21 CFR 211.67(b)
  2. The company had not validated its hand sanitizer manufacturing processes or qualified its equipment, and batch records did not match the formulation.

    21 CFR 211.100(a) and (b)
  3. The company did not test incoming components for identity and did not qualify suppliers or verify their certificates of analysis.

    21 CFR 211.84(d)(1) and (2)
  4. The quality-control group failed to ensure active-ingredient testing before release, investigations, change documentation, stability testing, and annual product reviews.

    21 CFR 211.22; 211.165(a); 211.192; 211.100(a); 211.166(a); 211.180(e)
  5. Secure Hand Sanitizer labeled as 70% isopropyl alcohol contained ethanol, substituting the active ingredient.

    FD&C Act section 501(d)(2)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective actions and prevention plans, or explain any delay and provide a completion schedule. If it resumes drug manufacturing, it must notify FDA before resuming.

Who should pay attention

  • brands or retailers that buy OTC hand sanitizer from contract manufacturers
  • suppliers of ethanol or isopropanol to drug manufacturers
  • quality teams at facilities that share equipment between drugs and industrial chemicals

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk
  2. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  3. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  4. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium